Boston Scientific Corporation

Valuation Analysis

About the Company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths,

Boston Scientific Corporation Stock at a Glance

Boston Scientific Corporation (BSX) is currently trading at $46.91 with a market capitalization of $69.7B. The trailing P/E ratio stands at 19.63x, with a forward P/E of 12.59x. The 52-week range spans from $45.99 to $109.50; the current price is 57.2% below the yearly high. Year-over-year revenue growth stands at +11.6%. The net profit margin stands at 17.29%.

💰 Dividend

Boston Scientific Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

30 analysts rate Boston Scientific Corporation (BSX) on consensus: Strong Buy. The average price target is $77.10, implying +64.36% from the current price. Analyst price targets range from $55.00 to $106.00.

Boston Scientific Corporation: The Investment Case in Detail

Boston Scientific Corporation (BSX) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 11.6% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 100% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 68.94%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Valuation in Context

With a PEG ratio of 0.57, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 12.59x is meaningfully below the trailing 19.63x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 64.36% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Boston Scientific Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.